Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa Timing for Bone Mineral Density in Prostate Cancer
NCT00582556Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2003
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in prostate cancer (PCa) (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Change in Bone Mineral Density of the Lumbar Spine and Femoral Neck at 2 years. Started Apr 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00582556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582556.